Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Abstract Text:

Y Kodama,A Maruta,

We obtain analytical formulas for minimizing chirp and timing jitter that lead to optimal designs for a soliton-wavelength-division-multiplexed system with dispersion management and lumped amplifiers. The method used here is the guiding-center theory, from which we obtain a stationary pulse shape (guiding-center soliton) that has enhanced power and an increased time-bandwidth product compared with those of a soliton alone.

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Publishing Authors By Initials

Y Kodama,A Maruta,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Optics letters

VOLUME: 22

Page Numbers: 1692-4

Journal Abbreviation:

ISSN: 0146-9592

DAY: 15

MONTH: Nov

YEAR: 1997

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7708433

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Optimal design of dispersion management for a soliton wavelength-division-multiplexed system. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Opt Lett

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Optimal design of dispersion management for a soliton wavelength-division-multiplexed system Related Publications

• An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
• Analysis of the conformational change of myosin during ATP hydrolysis using fluorescence resonance energy transfer.
• Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive.
• Chirped nonlinear pulse propagation in a dispersion-compensated system.
• Conformational change of the loop L5 in rice kinesin motor domain induced by nucleotide binding.
• Depression associated with chronic pain: incidence, characteristics, and long-term outcome.
• Effect of abdominal surgery on glucose tolerance, plasma levels of insulin and glycogenic amino acids.
• Formation and characterization of kinesin.ADP.fluorometal complexes.
• Incorporation of an azobenzene derivative into the energy transducing site of skeletal muscle myosin results in photo-induced conformational changes.
• Intermolecular cross-linking of a novel rice Kinesin k16 motor domain with a photoreactive ATP derivative.
• Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.
• PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.
• Photocontrol of Kinesin ATPase activity using an azobenzene derivative.
• Preparation and characterization of a novel rice plant-specific kinesin.
• Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
• Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
• The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.
• The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.